RetroSense Therapeutics Welcomes Dr. Steven Bramer as Chief Development Officer

RetroSense Therapeutics Welcomes Dr. Steven Bramer as Chief Development Officer

10/4/2012 10:19:18 AM

ANN ARBOR, Mich.-- RetroSense Therapeutics, a biotechnology company dedicated to developing gene therapy approaches to vision restoration welcomes Steven Bramer, PhD to its senior management team as Chief Development Officer.

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.